Swedish clinical-stage diabetes company Diamyd Medical (STO:DMYD-B) announced on Tuesday that it has received positive feedback from the US Food and Drug Administration (FDA) about an Accelerated Approval pathway for its immunotherapy, Diamyd, targeting Stage 3 Type 1 Diabetes patients with the HLA DR3-DQ2 genotype.
During a recent Type C Meeting, the FDA agreed that C-peptide could be used as a surrogate endpoint to predict the clinical benefit of preserving endogenous insulin production. This acknowledgment opens the possibility for Accelerated Approval based on significant treatment-related improvements in C-peptide levels due to Diamyd administration.
Ongoing discussions between Diamyd Medical and the FDA will clarify the requirements for a Biologics License Application (BLA) under this pathway, including an earlier readout from the ongoing Phase 3 DIAGNODE-3 trial.
Diamyd Medical focuses on precision medicine therapies for Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd has received Orphan Drug Designation and Fast Track Designation from the FDA for treating Stage 1, 2, and 3 Type 1 Diabetes.
The DIAGNODE-3 Phase III trial is currently recruiting patients with recent-onset Stage 3 Type 1 Diabetes in the US and eight European countries.
Amylyx receives EU Orphan Drug Designation for Wolfram syndrome treatment
KVK Tech registers Lomaira 8mg tablets in Mexico
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
M8 Pharmaceuticals signs exclusive licensing and distribution agreement with LG Chem
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
StimAire names new chief operating officer
TME Pharma to monetise clinical asset NOX-E36 for ophthalmology
Genentech reports positive Phase I Results for oral GLP-1 agonist CT-996